Treatment of base of tongue cancer with paclitaxel, ifosfamide, and cisplatinum induction chemotherapy followed by chemoradiotherapy

Laryngoscope

Volumn 118, Issue 8, 2008, Pages 1357-1361

  Hancock, Samuel Brandon ^a   Krempl, Greg A ^a   Canfield, Vikki ^a   Bogardus, Carl ^a   Kojouri, Kiarash ^a   Kaneaster, S K ^a   Medina, Jesus E ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Base of tongue; Carboplatin; Chemoradiation; Chemoradiotherapy; Cisplatin; Cisplatinum; Concurrent chemotherapy; Head and neck cancer; Hypopharynx; Ifosfamide; Induction chemotherapy; Oropharynx; Paclitaxel; Taxol; TIP; Tongue cancer

Indexed keywords

CISPLATIN; IFOSFAMIDE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DISTANT METASTASIS; DRUG DOSE SEQUENCE; DRUG EFFICACY; DYSPHAGIA; FATIGUE; FEMALE; FOLLOW UP; GASTROSTOMY; HEAD AND NECK CANCER; HICCUP; HUMAN; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NECK DISSECTION; NEUROPATHY; ODYNOPHAGIA; ORGAN PRESERVATION; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TONGUE CANCER; TREATMENT DURATION; TREATMENT RESPONSE; XEROSTOMIA; ADJUVANT THERAPY; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; NEUROLOGIC DISEASE; PATHOLOGY; SURVIVAL RATE; TONGUE TUMOR; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NERVOUS SYSTEM DISEASES; PACLITAXEL; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TONGUE NEOPLASMS;

EID: 49649104561     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLG.0b013e318175336a     Document Type: Article

References (7)

1. Wolf GT, Hong WK, Fisher SG, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The N Engl J Med 1991;324:1685-1690.
2. Forastiere AA, Maor M, Weber RS, et al. Long-term results of Intergroup RTOG 91-11: a phase II trial to preserve the larynx - induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol 2006;24:284s.
3. Machtay M, Rosethal DI, Hershock D, et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial. J Clin Oncol 2002;20:3964-3971.
4. Urba SG, Moon J, Giri PG, et al. Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial. J Clin Oncol 2005;23:88-95.
5. Cmelak AJ, Li S, Goldwasser MA, et al. Phase II Trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol 2007;25:3971-3976.
6. Shin DM, Glisson BS, Khuri FR, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head neck squamous cell carcinoma. J Clin Oncol 1998;16: 1325-1330.
7. Cmelak AJ, Murphy B, Burkey B, Shyr Y, Netterville J. Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial. Head Neck 2007;29: 315-324.